ÖÜ¿¯ 1997Äê1Ô´´¿¯£¨×ܵÚ323ÆÚ£© µÚ12¾í µÚ15ÆÚ 2008Äê4ÔÂ8ÈÕ³ö°æ


»ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽ÄÜÁ¦¼°
ϸ°ûºËת¼Òò×Ó¦ÊB±í´ïµÄÓ°Ïì¡ï

Ñ¹ú1£¬Áõ¸ïÐÂ1£¬¶­¹ûÐÛ2£¬¹ùÔÆÁ¼3


¿ÎÌâ±³¾°£º»ÆÜÎÊÇÓÃÓÚ·ÀÖÎÐÄÄÔѪ¹Ü¼²²¡µÄ´«Í³ÖÐÒ©¡£»ÆÜμ×ÜÕÊÇ´Ó»ÆÜÎÖÐÌáÈ¡µÄÓÐЧ³É·Ö£¬Æä·Ö×ӽṹÒÑÃ÷È·£¬µ«ÓйػÆÜμ×ÜÕ¶ÔÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõËðÉ˵ÄÓ°Ï챨µÀ½ÏÉÙ¡£

ͬÐÐÆÀ¼Û£º¸ÃÏîʵÑ齨Á¢ÁËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõÄ£ÐÍÄ£ÄâÆ÷¹Ù×é֯ȱѪ£­ÔÙ¹à×¢ËùÓÕµ¼µÄѪ¹Ü¸Ä±ä£¬´Ó·Ö×Óˮƽ̽ÌÖ»ÆÜμ×ÜÕ¶ÔѪ¹ÜÄÚÆ¤Ï¸°ûȱÑõ£¯¸´ÑõµÄ±£»¤×÷Óã¬ÎªÈ±ÑªÔÙ¹à×¢ËðÉ˵ÄÖÎÁÆÌṩÓÃÒ©ÒÀ¾Ý£¬ÊµÑé¾ßÓÐÒ»¶¨µÄ´´ÐÂÐÔ¡£

Ïà¹ØÁ´½Ó£ºÑõ»¯Ó¦¼¤¿É¼¤»îѪ¹ÜÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊBÐźÅתµ¼Í¨Â·£¬»î»¯µÄºËת¼Òò×Ó¦ÊBͨ·Óֿɵ¼ÖÂϸ°û¼ä𤸽·Ö×Ó1¹ý¶È±í´ï£¬ºóÕß½ø¶ø½éµ¼ÖÐÐÔÁ£Ï¸°ûµÄ𤸽ºÍ¾Û¼¯£¬Òý·¢Æ÷¹Ù¡¢×éÖ¯¼°Ï¸°ûµÄÑ×ÐÔËðÉË·´Ó¦¡£»ÆÜμ×ÜÕͨ¹ýÇå³ýÑõ×ÔÓÉ»ù£¬ÒÖÖÆºËת¼Òò×Ó¦ÊB·¢ÉúºËÒ×룬¼õÉÙϸ°û¼ä𤸽·Ö×Ó1µÄ±í´ï£¬´Ó¶ø¼õÇáѪ¹ÜÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽£¬¶ÔȱÑõ/¸´ÑõËðÉËѪ¹ÜÄÚÆ¤Ï¸°û¾ßÓб£»¤×÷Óá£

1Çൺ´óѧҽѧԺ»¤ÀíѧԺ£¬É½¶«Ê¡ÇൺÊÐ 266021£»Çൺ´óѧҽѧԺ¸½ÊôÒ½Ôº£¬2ÐÄÄÚ¿Æ£¬ 3ÄÔѪ¹Ü²¡Ñо¿Ëù£¬É½¶«Ê¡ÇൺÊÐ 266003

Ñ¹ú¡ï£¬ÄУ¬1970ÄêÉú£¬É½¶«Ê¡ÇൺÊÐÈË£¬ºº×壬Çൺ´óѧҽѧԺ¸½ÊôÒ½ÔºÐÄÄÚ¿ÆÔÚ¶Á˶ʿ£¬½²Ê¦£¬Ö÷Òª´ÓʹÚÐIJ¡µÄ»ù´¡ºÍÁÙ´²Ñо¿¡£
yfuguo@163.com


ÕªÒª
Ä¿µÄ: ²ÉÓÃÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõÄ£ÐÍÄ£ÄâÆ÷¹Ù×é֯ȱѪ-ÔÙ¹à×¢ËùÓÕµ¼µÄѪ¹Ü¸Ä±ä£¬¹Û²ì»ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËѪ¹ÜÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽¼°Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ïµÄ¸ÉÔ¤×÷Óá£
·½·¨£ºÊµÑéÓÚ2005-09/2006-05ÔÚÇൺ´óѧҽѧԺ¸½ÊôÒ½ÔºÄÔѪ¹Ü²¡Ñо¿Ëùϸ°ûÉúÎ﹤³ÌʵÑéÊÒ½øÐС£¢ÙʵÑé²ÄÁÏ£ºÐÂÉú¶ùÆê´ø£¨ÓÉÇൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¸¾²ú¿ÆÌṩ£¬²ú¸¾¼°Æä¼ÒÊôÖªÇéͬÒ⣬ʵÑé·ûºÏºÕ¶ûÐÁ»ùÐûÑÔÖеÄÂ×Àíѧ±ê×¼£©¡£¢ÚʵÑé¹ý³Ì¼°·Ö×飺ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÔ­´úÅàÑø£¬´«ÖÁ3´úºó£¬Ëæ»ú·ÖΪ3×é¡£¶ÔÕÕ×飺³£¹æÅàÑø£»È±Ñõ/¸´Ñõ×飺ÏÈȱÑõ´¦Àí1 h£¬ÔÙ¸´Ñõ1 h£»Ò©Îï¸ÉÔ¤×飺ÔÚÅàÑøÒºÖмÓÈëÖÕŨ¶È·Ö±ðΪ20£¬40£¬80 mg/LµÄ»ÆÜμ×ÜÕÔ¤´¦Àí£¬12 hºó½øÐÐȱÑõ/¸´Ñõ´¦Àí¡£¢ÛʵÑéÆÀ¹À£º·Ö±ðÓÃÁò´ú°Í±ÈÍ×·¨ºÍøÁªÃâÒßÎü¸½ÊÔÑé²â¶¨Ï¸°ûÅàÑøÒºÖбû¶þÈ©µÄº¬Á¿ºÍϸ°û¼ä𤸽·Ö×Ó1Ũ¶È£»ÃâÒß»¯Ñ§·¨²âÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊBµÄ±í´ï£»»¢ºìȾɫ·¨¼ì²âÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽¡£
½á¹û£º¢ÙÓë¶ÔÕÕ×é±È½Ï£¬È±Ñõ/¸´Ñõ×éϸ°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿Ôö¶à£¨P < 0.01£©£»Ëæ×Å»ÆÜμ×ÜÕÔ¤´¦Àí¼ÁÁ¿µÄÔö¼Ó£¬±û¶þÈ©º¬Á¿½µµÍ£¨P < 0.01£©£¬³Ê¼ÁÁ¿ÒÀÀµÐÔ¡£¢ÚÓë¶ÔÕÕ×é±È½Ï£¬È±Ñõ¸´Ñõ×éÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ӧʦ¢ÑôÐÔϸ°ûÂÊ¡¢Ï¸°ûÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¼°ÖÐÐÔÁ£Ï¸°û𤸽ÂÊÉý¸ß£¨P¾ù< 0.01£©£»Ëæ×Å»ÆÜμ×ÜÕÔ¤´¦Àí¼ÁÁ¿µÄÔö¼Ó£¬ºËת¼Òò×Ó ¦ÊB±í´ïÑôÐÔϸ°ûÂÊ¡¢ÖÐÐÔÁ£Ï¸°û𤸽ÂÊϽµ£¨P < 0.05»òP < 0.01£©£¬Ï¸°û¼ä𤸽·Ö×Ó1Ũ¶È¼õÉÙ£¨P < 0.01£©£¬³Ê¼ÁÁ¿ÒÀÀµÐÔ¡£
½áÂÛ£º»ÆÜμ×ÜÕͨ¹ýÒÖÖÆÈ±Ñõ¸´ÑõÒýÆðµÄѪ¹ÜÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ï£¬¼õÇáѪ¹ÜÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽£¬¶ÔȱÑõ/¸´ÑõËðÉËѪ¹ÜÄÚÆ¤Ï¸°û¾ßÓб£»¤×÷Óã¬ÇҳʼÁÁ¿ÒÀÀµÐÔ¡£
¹Ø¼ü´Ê£º»ÆÜμ×ÜÕ£»ÄÚÆ¤Ï¸°û£»È±Ñõ/¸´Ñõ£»NF-¦ÊB£»°û¼äÕ³¸½·Ö×Ó1£»×éÖ¯¹¹½¨

Ñ¹ú£¬Áõ¸ïУ¬¶­¹ûÐÛ£¬¹ùÔÆÁ¼. »ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽ÄÜÁ¦¼°Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ïµÄÓ°Ïì[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(15):2843-2846
[www.zglckf.com/zglckf/ejournal/upfiles/08-15/15k-2843(ps).pdf]

ÖÐͼ·ÖÀàºÅ:R329.4
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)15-02843-04

ÊÕ¸åÈÕÆÚ£º2008-01-05 ¡¡ÐÞ»ØÈÕÆÚ£º2008-02-02
(08-50-1-97/W¡¤Q)


Effect of astragaloside on adhesion of human umbilical vein endothelial cells and polymorphonuclear neutrophils and expression of nuclear factor kappa B under hypoxia/reoxygenation condition

Abstract


AIM:To investigate the intervention effect of astragaloside on adhesion of polymorphonuclear neutrophils (PMN) and vascular endothelial cells and on expression of nuclear factor-¦ÊB (NF-¦ÊB) in human umbilical vein endothelial cells (hUVECs) injured by hypoxia/reoxygenation due to ischemia/reperfusion.
METHODS: The experiment was performed at the Cell Bioengineering Laboratory of Institute of Cerebrovascular Diseases, Affiliated Hospital of Medical College, Qingdao University from September 2005 to May 2006. ¢ÙNeonatal umbilical cords were offered by Department of Gynecology and Obstetrics in Affiliated Hospital of Medical College of Qingdao University, with informed consent of puerperant and their families. The experiment was accorded with ethical standard of Helsinki declaration. ¢ÚThe hUVECs were cultured to the future passage. After the third passage, hUVECs were randomly divided into three groups. Cells in a control group were cultured under normal conditions; Cells in a hypoxia/reoxygenation group were cultured under in closed container with hypoxia for 1 hour, and then under normal conditions for 1 hour; The hUVECs in a astragaloside group were pretreatment by different doses of astragaloside (20, 40, 80 mg/L). After 12 hours, hUVECs suffered from hypoxia/reoxygenation. ¢ÛThe concentration of intercellular adhesion molecule (ICAM)-1 and content of malondialdehyde (MDA) in supernatant were detected by enzyme linked immunosorbent assay (ELISA) and thiobarbituric acid method. Expression of NF-¦ÊB of hUVECs was analyzed by immunohistochemistry. PMN adhesion to hUVECs was measured by rose Bengal staining.
RESULTS: ¢ÙCompared to the control group, the content of MDA remarkably increased in hypoxia/reoxygenation group (P < 0.01). With the increased dose of astragaloside, MDA content decreased (P < 0.01) with a dose-dependent effect. ¢ÚCompared to the control group, the percentage of NF-¦ÊB positive endothelial cells, concentration of ICAM-1 and adhesion rate of hUVECs to PMN increased in the hypoxia/reoxygenation group (P < 0.01). With the increased dose of astragaloside, the percentage of NF-¦ÊB positive endothelial cells and adhesion rate of hUVECs to PMN decreased (P < 0.05 or P < 0.01), and concentration of ICAM-1 was reduced (P < 0.01) with a dose-dependent effect.
CONCLUSION: Astragaloside can protect vascular endothelial cells from the injury caused by hypoxia/reoxygenation by inhibiting expression of NF-¦ÊB induced by hypoxia/reoxygenation in vascular endotheliial cells and by reducing the adhesion of vascular endotheliial cells to PMN with a dose-dependent effect.

Yang FG, Liu GX, Dong GX, Guo YL. Effect of astragaloside on adhesion of human umbilical vein endothelial cells and polymorphonuclear neutrophils and on expression of nuclear factor kappa B under hypoxia/reoxygenation condition.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(15):2843-2846(China)
[www.zglckf.com/zglckf/ejournal/upfiles/08-15/15k-2843(ps).pdf]

0 ÒýÑÔ

»ÆÜεÄÓÐЧ³É·Ö¸´ÔÓ£¬Ö÷ÒªÓÐÔíÜÕÀà¡¢»ÆÍªÀà¡¢¶àÌǵȡ£ÏÖ´úҽѧÑо¿·¢ÏÖ,»ÆÜβ»Í¬ÌáÈ¡Îï¾ßÓп¹Ñõ»¯¡¢¿¹Ñס¢À©Ñª¹Ü¡¢¸ÄÉÆÐÄÔàȱѪÐÔ¼²²¡µÄ×÷ÓÃ[1-3]¡£»ÆÜμ×ÜÕÊÇ´Ó»ÆÜÎ×ÜÜÕÖзÖÀëµÃµ½µÄÒ»À൥Ì廯ºÏÎÆä¶ÔÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõËðÉ˵ÄÓ°Ï챨µÀ½ÏÉÙ¡£±¾ÊµÑé²ÉÓÃÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõÄ£ÐÍÄ£ÄâÆ÷¹Ù×é֯ȱѪ-ÔÙ¹à×¢ËùÓÕµ¼µÄѪ¹Ü¸Ä±ä£¬¹Û²ì»ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÅàÑøÒºÖбû¶þÈ©µÄº¬Á¿ºÍϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¡¢Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ïÒÔ¼°ÓëÖÐÐÔÁ£Ï¸°û𤸽ÂʵÄÓ°Ï죬´Ó·Ö×Óˮƽ̽ÌÖ»ÆÜμ×ÜÕ¶ÔѪ¹ÜÄÚÆ¤Ï¸°ûȱÑõ/¸´ÑõµÄ±£»¤×÷Óá£

1 ²ÄÁϺͷ½·¨

Éè¼Æ£ºËæ»ú¶ÔÕÕʵÑé¡£
µ¥Î»£ºÇൺ´óѧҽѧԺ»¤ÀíѧԺÄÚ¿ÆÑ§½ÌÑÐÊÒ¡£
²ÄÁÏ£ºÊµÑéÓÚ2005-09/2006-05ÔÚÇൺ´óѧҽѧԺ¸½ÊôÒ½ÔºÄÔѪ¹Ü²¡Ñо¿Ëùϸ°ûÉúÎ﹤³ÌʵÑéÊÒ(ɽ¶«Ê¡ÖصãʵÑéÊÒ£¬BSL-2)Íê³É¡£ÐÂÉú¶ùÆê´ø(ÓÉÇൺ´óѧҽѧԺ¸½ÊôÒ½Ôº¸¾²ú¿ÆÌṩ£¬²ú¸¾¼°Æä¼ÒÊôÖªÇéͬÒ⣬ʵÑé·ûºÏºÕ¶ûÐÁ»ùÐûÑÔÖеÄÂ×Àíѧ±ê×¼)¡£Ò©Æ·ÓëÖ÷ÒªÊÔ¼Á£º»ÆÜμ×ÜÕ(ÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¬ÅúºÅ£º0781-200311)£»DMEMÅàÑø»ù(ÃÀ¹úGibco¹«Ë¾)£»±û¶þÈ©¼ì²âÊÔ¼ÁºÐ¡¢Ï¸°û¼ä𤸽·Ö×Ó1 ÊÔ¼ÁºÐ£¨ÄϾ©½¨³ÉÉúÎ﹤³ÌÑо¿Ëù£©£»À±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄÑò¿¹ÍÃIgG¡¢ÃâÒß×éÖ¯»¯Ñ§ÊÔ¼ÁºÐ¡¢¶þ°±»ùÁª±½°·ÏÔÉ«ÊÔ¼ÁºÐ¡¢ºËת¼Òò×Ó¦ÊB p65¶à¿Ë¡¿¹Ìå(Î人²©Ê¿µÂÉúÎ﹤³ÌÓÐÏÞ¹«Ë¾)£»»¢ºì(±±¾©ÊÔ¼Á¹«Ë¾)µÈ¡£Ö÷ÒªÒÇÆ÷£ºSw-CJ-TA³¬¾»¹¤×÷̨£¨Îâ½­Êо»»¯É豸×ܳ§£©£¬CO2ÅàÑøÏäMCO-17AICÐÍ(ÈÕ±¾Sanyo¹«Ë¾Éú²ú)£»IX-70 ÐÍÓ«¹âµ¹ÖÃÏÔ΢¾µ(ÈÕ±¾Olympus¹«Ë¾Éú²ú)£»Sartorius BS110Ð͵ç×ÓÌìÆ½(µÂ¹ú)£¬BeckmanµÍεÍËÙÀëÐÄ»ú(Beckman¹«Ë¾)µÈ¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÉè¼ÆÎªµÚÒ»¡¢Èý×÷Õߣ¬ÊµÊ©ÎªµÚÒ»¡¢¶þ×÷Õߣ¬ÆÀ¹ÀΪµÚÈý¡¢ËÄ×÷Õß¡£ËùÓÐ×÷Õß¾ù¾­Õý¹æÅàѵ£¬¾ß±¸»ù±¾µÄʵÑé¼¼Êõ¡£
¼¼Êõ·Ïߣº
ÈËÆê¾²ÂöÄÚÆ¤Ï¸°û·ÖÀë¡¢¼ø¶¨ºÍÅàÑø£ºÈËÆê¾²ÂöÄÚÆ¤Ï¸°û²ÉÓøÄÁ¼µÄJaffe ·½·¨¡£ÔÚÎÞ¾úÌõ¼þÏÂÈ¡½¡¿µ²ú¸¾Õý³£·ÖÃäÌ¥¶ùÆê´ø25~30 cm£¬ÓÃHank¡¯sÒº³åÏ´¸É¾»£¬¹àÈë1 g/LµÄ¢ñÐͽºÔ­Ã¸£¬ÔÚ37 ¡æ ÎÂÏäÖÐÅàÑø18~20 min£¬ÊÕ¼¯Ïû»¯Òº£¬1 000 r/min£¨ÀëÐİ뾶20 cm£©ÀëÐÄ10 min£¬ÆúÉÏÇ壬¼ÓÈ뺬Ìå»ý·ÖÊý0.20СţѪÇåºÍÉú³¤Òò×ÓµÄDMEMÅàÑøÒºÖÆ³Éϸ°ûÐüÒº£¬ÖÃ37 ¡æÅàÑøÏ䣨º¬Ìå»ý·ÖÊý0.95 O2+0.05 CO2£©ÖнøÐÐÅàÑø£¬24 hºó»»Òº£¬´ýϸ°û³¤³ÉÈÚºÏ״̬ºó×÷ϸ°û¼ø¶¨¡£Ñª¹ÜÄÚÆ¤Ï¸°ûÌØÕ÷£ºÏà²îÏÔ΢¾µÏ³ʵ¥²ãÆÌ·ʯÑùÅÅÁУ¬ÓÃÃâÒß·¨²â¶¨µÚ¢øÒò×ÓÏà¹Ø¿¹Ô­³ÊÑôÐÔ·´Ó¦¡£È·¶¨ÎªÄÚÆ¤Ï¸°ûºóÔÙ´«´úÅàÑø£¬È¡µÚ3´úÉú³¤Á¼ºÃµÄÈËÆê¾²ÂöÄÚÆ¤Ï¸°û½øÈëʵÑé¡£
ȱÑõ/¸´ÑõËðÉËÄ£Ð͵Ľ¨Á¢£ºÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÉú³¤ÖÁ80%ÒÔÉÏÈںϵĵ¥²ãϸ°ûʱ£¬Ïû»¯ÖƳɵ¥Ï¸°ûÐüÒº£¬µ÷Õûϸ°ûÃܶÈΪ2.0¡Á105 L-1£¬·Ö±ð½ÓÖÖÓÚÔ¤ÏÈÓöà¾ÛÀµ°±Ëá°ü±»µÄ24¿×°å¡£24 ¿×°åÿ¿×¼ÓÈë200 ¦ÌL ϸ°ûÐüÒº£¬´ÎÈÕ»»Òº£¬µÚ3 Ìì½øÐÐÔìÄ£¡£ÖÃÓÚ×ÔÖÆµÄ37 ¡æ ÃܱÕȱÑõ¹ÞÖУ¬³ÖÐøÍ¨ÈëȱÑõ»ìºÏÆøÌ壨º¬Ìå»ý·ÖÊý0.05 CO2+0.95 N2£©0.5 L/min£¬Öû»ÈÝÆ÷ÖеÄÑõÆø¡£´ý¸ÃÈÝÆ÷ÄÚÑõÆøÌå»ý·ÖÊýµÍÓÚ0.01ºó£¬Í£Ö¹Í¨ÈëȱÑõ»ìºÏÆøÌå¡£ÃܱոÃÈÝÆ÷£¬ÖÃÓÚ37 ¡æÏ¸°ûÅàÑøÏäÖÐÅàÑø1 h£¬ÔÙ´ò¿ªÈÝÆ÷£¬½«24¿×ÅàÑø°åÖÃÓÚÕý³£ÅàÑøÌõ¼þµÄÅàÑøÏäÖУ¨º¬Ìå»ý·ÖÊý0.95µÄO2+0.05µÄCO2£©ÅàÑø£¬½øÐи´Ñõ´¦Àí¡£
ʵÑé·Ö×éÓëÒ©Îï¸ÉÔ¤£ºÊµÑéËæ»ú·ÖΪ£º¢Ù¶ÔÕÕ×飺ÖÃÓÚ37 ¡æÌå»ý·ÖÊý0.95 O2+0.05 CO2µÄÅàÑøÏäÖÐÕý³£ÅàÑøÏàÓ¦µÄʱ¼ä¡£¢ÚȱÑõ¸´Ñõ×é£ºÖÆ±¸È±Ñõ¸´ÑõÄ£ÐÍ£¬ÖÃÓÚÌå»ý·ÖÊý0.95µÄN2+0.05µÄCO2ȱÑõ»·¾³1 h£¬È»ºóÖÃÓÚÕý³£ÅàÑøÌõ¼þµÄÅàÑøÏäÖмÌÐøÅàÑø1 h¡£¢ÛÒ©Îï¸ÉÔ¤×飺·ÖΪ3¸öÑÇ×飬ÔÚÅàÑøÒºÖмÓÈëÖÕŨ¶È·Ö±ðΪ20£¬40£¬80 mg/LµÄ»ÆÜμ×ÜÕ£¬Ô¤´¦Àí12 h£¬È»ºóͬȱÑõ¸´Ñõ×é´¦Àí¡£Ã¿×é6Àý£¬ÊµÑéÖØ¸´2´Î¡£
ϸ°ûÅàÑøÉÏÇåÖбû¶þÈ©º¬Á¿ºÍϸ°û¼ä𤸽·Ö×Ó1Ũ¶ÈµÄ¼ì²â£ºÊÕ¼¯¸÷×éÅàÑøÏ¸°ûÉÏÇåÒº£¬°´Ã¿·Ý1 mL·Ö×°£¬ÖÃ-70 ¡æ ¶³´æ±¸ÓᣲÉÓÃøÁªÃâÒßÎü¸½¼¼ÊõË«¿¹Ìå¼ÐÐÄ·¨£¨ABC-ELISA£©²â¶¨Ï¸°ûÅàÑøÉÏÇåÒºÖбû¶þÈ©º¬Á¿ºÍϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¡£¾ßÌå¼ì²â²½Öè°´ÊÔ¼ÁºÐ˵Ã÷²Ù×÷£¬ÓÃø±êÒDzâµÃ¸÷¿×450 nm´¦AÖµ£¬¸ù¾Ý²»Í¬Å¨¶È±ê׼ƷµÄA 450 nmÖµ×ö±ê×¼ÇúÏߣ¬¼ÆËã³öÑùÆ·ÖÐϸ°û¼ä𤸽·Ö×Ó1µÄŨ¶È¡£Áò´ú°Í±ÈÍ×·¨²â±û¶þÈ©º¬Á¿£¬¾ßÌå¼ì²â²½Öè°´ÊÔ¼ÁºÐ˵Ã÷²Ù×÷¡£
ÃâÒß×éÖ¯»¯Ñ§¼ì²âºËת¼Òò×Ó¦ÊBµÄ±í´ï£º¸ù¾Ý²©Ê¿µÂÉúÎ﹤³Ì¹«Ë¾ÌṩµÄÉúÎïÒÖµ°°×ËØ¹ýÑõ»¯Îïø·¨(SABC)ÃâÒß×éÖ¯»¯Ñ§È¾É«ÊÔ¼ÁºÐ˵Ã÷ÊéÒªÇó½øÐС£±ê±¾ÓÃ50 g/L¶à¾Û¼×È©¹Ì¶¨20 min£¬²ÉÓúËת¼Òò×Ó¦ÊB p65¶à¿¹ÔÚ4 ¡æ ¹ýÒ¹£¬ÔÙÓÃÉúÎïËØ±ê¼ÇµÄÑò¿¹Íÿ¹Ì屣Σ¬¶þ°±»ùÁª±½°·È¾É«£¬ÔÚÏÔ΢¾µÏ¼ì²â£¬ºË¿Õ°×»ò³Ê¾ùÔÈÈõµ­ºÖɫΪÒõÐÔϸ°û£¬ºËÄÚ³öÏÖרºÖÉ«¿ÅÁ£ÎªÑôÐÔϸ°û£¬¸ß±¶¾µÏ¹۲ì10¸ö¸ß±¶ÊÓÒ°£¬¼ÆËãÑôÐÔϸ°ûÕ¼ËùÓÐϸ°ûµÄ±ÈÂÊ¡£
ÈËÖÐÐÔÁ£Ï¸°ûµÄ·ÖÀë¼°ÆäÓëÈËÆê¾²ÂöÄÚÆ¤Ï¸°û𤸽ÊÔÑ飺ȡ½¡¿µÈ˾²ÂöѪ20 mL£¬¸ÎËØ¿¹Äý£¬ÓÃPercol1·ÖÀëÒº·ÖÀëÖÐÐÔÁ£Ï¸°û£¬Á×ËáÑλº³åҺϴµÓ2±éºóÖØÐüÓÚÌå»ý·ÖÊýΪ0.05̥ţѪÇåµÄDMEMÅàÑøÒºÖУ¬µ÷Õûϸ°ûÊýΪ2.5¡Á10 9 L-1¡£GiemsaȾɫÖÐÐÔÁ£Ï¸°û´¿¶È90%ÒÔÉÏ£¬×¶³æÀ¶È¾É«Ï¸°û»îÁ¦´óÓÚ95%£¬·ûºÏÊÔÑéÒªÇó¡£ÈËÆê¾²ÂöÄÚÆ¤Ï¸°û´¦Àí½áÊøºó£¬ÎüÆú¸÷¿×ÒºÌ壬Á×ËáÑλº³åҺϴ¿×3´Î£¬¼ÓÈëÖÐÐÔÁ£Ï¸°ûÐüÒº200 ¦ÌL£¨5.0¡Á105¸ö£©£¬37 ¡æ ·õÓý30 min¡£Îü³ýδ𤸽µÄÖÐÐÔÁ£Ï¸°û£¬Á×ËáÑλº³åҺϴ3´Î£¬Ã¿¿×¼ÓÈë0.25% »¢ºì£¨Á×ËáÑλº³åÒºÅäÖÆ£©100 ¦ÌL£¬ÊÒηõÓý5 min¡£Îü³ýȾÁÏ£¬Á×ËáÑλº³åҺϴ3´Î£¬¼ÓÈëÁ×ËáÑλº³åÒº-ÒÒ´¼£¨1¡Ã1£©£¬Ã¿¿×200 ¦ÌL£¬ÊÒηõÓý30 min£¬Ã¸±êÒÇ570 nm ²¨³¤²â¶¨¸÷¿×AÖµ¡£ÖÐÐÔÁ£Ï¸°ûËùÉãÈ¡µÄ»¢ºìȾÁÏÔÚÁ×ËáÑλº³åÒº-ÒÒ´¼×÷Óúó¿ÉÊͷųöÀ´£¬Òò´Ë£¬Ã¿¿×AÖµÓëËù𤸽µÄÖÐÐÔÁ£Ï¸°ûÊýÁ¿³ÉÕý±È£¬¼ÆËã¸÷×éµÄϸ°û𤸽ÂÊ¡£ð¤¸½ÂÊ=£¨ÈËÆê¾²ÂöÄÚÆ¤Ï¸°û𤸽ÖÐÐÔÁ£Ï¸°ûAÖµ£­ÈËÆê¾²ÂöÄÚÆ¤Ï¸°û AÖµ£©/¼ÓÈë×ÜÖÐÐÔÁ£Ï¸°ûAÖµ¡Á100%¡£
Ö÷Òª¹Û²ìÖ¸±ê£º¢Ù»ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÅàÑøÒºÖбû¶þÈ©µÄº¬Á¿¡¢Ï¸°û¼ä𤸽·Ö×Ó1º¬Á¿¼°ÖÐÐÔÁ£Ï¸°û𤸽ÂʵÄÓ°Ïì¡£¢Ú»ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ïµÄÓ°Ïì¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷Õß²ÉÓÃSPSS 11.5Èí¼þ½øÐз½²îÆëÐÔ¼ìÑé¡¢µ¥ÒòËØ·½²î·ÖÎö£¬×é¼ä±È½ÏÓÃLSD·¨¡£

2 ½á¹û

2.1 »ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿µÄÓ°Ïì Óë¶ÔÕÕ×é[(2.38¡À0.49) ¦Ìmol/L]±È½Ï£¬È±Ñõ¸´Ñõ×éÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿ÏÔÖøÉý¸ß£¨P < 0.01£©¡£ÓëȱÑõ¸´Ñõ×é±È½Ï£¬Ò©Îï¸ÉÔ¤×éËæ×Å»ÆÜμ×ÜÕÔ¤´¦ÀíŨ¶ÈµÄÔö¼Ó£¬Ï¸°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿Ã÷ÏÔ½µµÍ[(ȱÑõ/¸´Ñõ×éºÍ»ÆÜμ×ÜÕ20£¬40£¬80 mg/L×éÒÀ´ÎΪ£º(6.98¡À1.15)£¬(4.38¡À0.83)£¬(3.25¡À0.66)£¬(2.22¡À0.58) ¦Ìmol/L£¬P < 0.01]£¬¸ÃЧӦÓë»ÆÜμ×ÜÕÔ¤´¦ÀíŨ¶È³Ê¼ÁÁ¿ÒÀÀµÐ§Ó¦¡£
2.2 »ÆÜμ×ÜÕ¶ÔȱÑõ/¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ï¡¢Ï¸°ûÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¼°ÓëÖÐÐÔÁ£Ï¸°û𤸽ÂʵÄÓ°Ïì ¼û±í1¡£

 

Õý³£Ï¸°û×é°û½¬ÓÐÑôÐÔȾɫ£¬¶àÊýϸ°û°ûºËÎÞÃ÷ÏÔµÄȾɫ£¬ÉÙÊýϸ°ûºËÓÐÒ»¶¨³Ì¶ÈµÄȾɫ¡£È±Ñõ¸´Ñõºó£¬¶àÊý°ûºË³ÊÏÖÃ÷ÏÔµÄÑôÐÔȾɫ¡£Óë¶ÔÕÕ×éÏà±È£¬È±Ñõ¸´Ñõ×éÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊBÑôÐÔϸ°ûÂÊ¡¢Ï¸°ûÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¼°ÓëÖÐÐÔÁ£Ï¸°û𤸽ÂÊÏÔÖøÉý¸ß£¨P ¾ù< 0.01£©¡£ÓëȱÑõ¸´Ñõ×é±È½Ï£¬Ò©Îï¸ÉÔ¤×éËæ×Å»ÆÜμ×ÜÕÔ¤´¦ÀíŨ¶ÈµÄÔö¼Ó£¬ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûºËת¼Òò×Ӧʦ¢±í´ïÑôÐÔϸ°ûÂʼõÉÙ£¨P < 0.05»òP < 0.01£©¡¢Ï¸°ûÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö×Ó1Ũ¶È¼õÉÙ£¨P < 0.01£©¡¢ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽ÂÊϽµ£¨P < 0.01£©£¬¸ÃЧӦÓë»ÆÜμ×ÜÕÔ¤´¦ÀíŨ¶È³Ê¼ÁÁ¿-ÒÀÀµÐ§Ó¦¡£

3 ÌÖÂÛ

Õý³£Çé¿öÏ£¬ÄÚÆ¤Ï¸°ûËù¾ßÓеĿ¹Ñõ»¯»úÖÆ¿ÉÇå³ý»îÐÔÑõ£¨°üÀ¨H2O2¡¢OH-¡¢O2- µÈÑõ×ÔÓÉ»ù£©£¬Î¬³Öϸ°ûÑõ»¯»¹Ô­×ÔÎÈ̬£¬Òò¶ø²»»á·¢ÉúÓк¦×÷Óá£ÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõʱÑõ×ÔÓÉ»ùÉú³ÉÔö¼Ó£¬ÕâЩÑõ×ÔÓÉ»ù×÷ÓÃÓÚϸ°ûĤ¿ÉÒýÆðÖ¬ÖʹýÑõ»¯·´Ó¦£¬²úÉú´óÁ¿±û¶þÈ©£¬ÇÒÑõ×ÔÓÉ»ùÄܼ¤»îϸ°ûÄÚµ°°×¼¤Ã¸ºÍת¼Òò×Ó£¬½éµ¼Ò»ÏµÁÐÉúÎï·´Ó¦¡£±û¶þÈ©º¬Á¿µÄ±ä»¯ÔÚijÖ̶ֳÈÉÏ¿ÉÒÔÁ˽â»úÌåÄÚÑõ»¯·´Ó¦µÄÇ¿Èõ¡£±¾ÊµÑé½á¹ûÏÔʾ£º¾­È±Ñõ¸´Ñõ´¦ÀíµÄÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿ÏÔÖøÔö¼Ó£¬ÌáʾȱÑõ¸´ÑõʹÑõ×ÔÓÉ»ùÉú³ÉÔö¶à£¬ÄÚÆ¤Ï¸°û·¢ÉúÖ¬ÖʹýÑõ»¯£»²»Í¬Å¨¶È»ÆÜμ×ÜÕÔ¤´¦Àíºó£¬Ï¸°ûÅàÑøÒºÖбû¶þÈ©º¬Á¿Ï½µ£¬ÇÒÆä×÷ÓþßÓÐŨ¶ÈÒÀÀµÐÔ¡£ÒÑÓÐÑо¿±íÃ÷»ÆÜμ×ÜÕ¾ßÓÐÇå³ýÑõ×ÔÓÉ»ù£¬¿¹Ö¬ÖʹýÑõ»¯×÷ÓÃ[4]¡£»ÆÜμ×ÜÕ¿ÉÄÜͨ¹ý¼ÓÇ¿ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÇå³ýÑõ×ÔÓÉ»ùµÄÄÜÁ¦£¬Ê¹Ö¬ÖʹýÑõ»¯×÷ÓüõÇᣬ¹ÊÅàÑøÒºÖбû¶þÈ©º¬Á¿Ï½µ¡£
ºËת¼Òò×Ó¦ÊBÊÇÒ»¸ö¶à¹¦ÄܺËת¼Òò×Ó, ΪRelµ°°×¼Ò×å³ÉÔ±, ÓɶàëÄP50 ºÍP65 ÑÇ»ùÐγÉͬԴÐÔ»òÒìÔ´ÐÔ¶þ¾ÛÌå¡£ºËת¼Òò×Ó¦ÊB¾ßÓй㷺µÄÉúÎïѧ»îÐÔ£¬ÔÚÄÚÆ¤Ï¸°ûµÄ»î»¯ÖоßÓÐÖØÒªµÄ×÷Óà [5]¡£Ò»°ãÇé¿öÏ£¬ºËת¼Òò×Ó¦ÊBÓëÆäÒÖÖÆµ°°×£¨I¦ÊB£©½áºÏ£¬ÒÔÎÞ»îÐÔÐÎʽ´æÔÚÓÚϸ°ûµÄ°û½¬ÖС£ÒÑÓÐÑо¿±íÃ÷£¬Ðļ¡È±ÑªÔÙ¹à×¢Äܼ¤»îºËת¼Òò×Ó¦ÊB£¬Æä¼¤»îÒòËØ¿ÉÄÜΪÐļ¡È±ÑªÔÙ¹à×¢ºóÔì³ÉµÄÑõ»¯Ó¦¼¤¡¢¸´Ñõ¡¢ÄÚÖÊÍø¸ÆÀë×Ó³¬ÔØ¡¢ÓÎÀë»ùºÍÄÚ¶¾ËصÈ[6]¡£È±Ñõ¸´Ñõʱ²úÉúµÄÑõ×ÔÓÉ»ù¿Éʹ¢ñ¦ÊBÁ×Ëữˮ½â£¬´Ó¶øÓëºËת¼Òò×Ó¦ÊB·¢Éú½âÀ룬µ¼ÖºËת¼Òò×Ӧʣ·¢ÉúºËÒ×룬½øÈëϸ°ûºËÓë°Ð»ùÒòÆô¶¯Çø»òÔöÇ¿×ÓÉϵĺËת¼Òò×Ó¦ÊB½áºÏλµã½áºÏ£¬´Ùʹϸ°û±íÃæÊÜÌ塢𤸽·Ö×ÓºÍϸ°ûÒò×ӵıí´ï [7-11]¡£Ê¹ÓúËת¼Òò×Ó¦ÊB¼¤»îÒÖÖÆ¼ÁßÁ¿©¶þÁò°±»ù¼×Ëáõ¥(PDTC)¿ÉʹºËת¼Òò×Ó¦ÊB»îÐÔÃ÷ÏÔ½µµÍ£¬¼õÇáÖÐÐÔÁ£Ï¸°û𤸽ºÍ½þÈó£¬È±ÑªÔÙ¹à×¢ËðÉËÏÔÖø¼õÇá¡£
ϸ°û¼ä𤸽·Ö×Ó1ÊôÓÚÃâÒßÇòµ°°×³¬»ùÒò¼Ò×å³ÉÔ±£¬Ö÷Òª±í´ïÓÚѪ¹ÜÄÚÆ¤Ï¸°û¡£Ï¸°û¼ä𤸽·Ö×Ó1ÔÚÉúÀíÌõ¼þÏ´¦Óڵͱí´ï״̬£¬µ±´ÙÑ×ÐÔ½éÖÊÈç»îÐÔÑõ¡¢Ö×Áö»µËÀÒò×Ó¦Á¡¢°×ϸ°û½éËØ1´Ì¼¤Ï±í´ïÔöÇ¿[12]£¬²¢ÇÒÄÜÔÚÄÚÆ¤Ï¸°ûÉϳÖÐø±í´ï£¬ÓëÖÐÐÔÁ£Ï¸°û±íÃæµÄÕûºÏËØ¼Ò×åCD11/CD18Á¬½Ó£¬Ê¹ÖÐÐÔÁ£Ï¸°ûÓëÄÚÆ¤Ï¸°ûÀιÌ𤸽£¬ÓÕµ¼ÄÚÆ¤Ï¸°û¹Ç¼ÜÏà¹Øµ°°×ÀÒ°±ËáÁ×Ëữ£¬ÒýÆðϸ°û¹Ç¼ÜµÄ¸Ä±ä£¬ÓÐÀûÓڻÖÐÐÔÁ£Ï¸°û´©¹ýÄÚÆ¤Ï¸°û¼°»ùĤÏò¾Ö²¿×éÖ¯¾Û¼¯½þÈ󣬵¼ÖÂ΢Ѫ˨ÐγɺÍëϸѪ¹Ü×èÈû£¬ÒýÆðÈ±ÑªÇøÎÞ¸´Á÷ÏÖÏóµÄ·¢Éú¡£Í¬Ê±£¬ð¤¸½¼¤»îµÄÖÐÐÔÁ£Ï¸°ûÊÍ·ÅÑõ×ÔÓÉ»ù¡¢µ¯ÐÔµ°°×ø¡¢µ°°×Ë®½âøµÈϸ°û¶¾ÐÔÎïÖÊ£¬¼ÓÖØÄÚÆ¤Ï¸°ûºÍÐļ¡Ï¸°ûµÄËðÉË[13-20]¡£Ï¸°û¼ä𤸽·Ö×Ó1µÄ±í´ï¾ö¶¨ÁËÖÐÐÔÁ£Ï¸°ûµÄ½þÈó³Ì¶È¡£
±¾ÊµÑé²ÉÓÃÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõÄ£ÐÍÄ£ÄâÆ÷¹Ù×é֯ȱѪ-ÔÙ¹à×¢ËùÓÕµ¼µÄѪ¹Ü¸Ä±ä£¬½á¹ûÏÔʾ²»Í¬Å¨¶È»ÆÜμ×ÜÕ´¦Àíºó£¬ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûȱÑõ¸´ÑõºËת¼Òò×Ó¦ÊB ±í´ï½µµÍ£¬Ï¸°ûÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö×Ó£±µÄŨ¶È¼õÉÙ£¬ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽ÂʽµµÍ¡£ÌáʾÄÚÆ¤Ï¸°ûµÄºËת¼Òò×Ó¦ÊB»îÐԱ仯ÓëÐļ¡ÔÙ¹à×¢ËðÉËÓйأ¬²¢ÔÚת¼ˮƽÉÏ˵Ã÷ÄÚÆ¤Ï¸°ûȱÑõ¸´Ñõʱ´æÔÚºËת¼Òò×Ó¦ÊB»î»¯µÄÐźŴ«µ¼Í¾¾¶¡£ºËת¼Òò×Ó¦ÊB±»¼¤»îºó£¬Í¨¹ýµ÷¿ØÏ¸°û¼ä𤸽·Ö×Ó1µ°°×µÄ±í´ï¶ø²ÎÓëÔÙ¹à×¢ËðÉ˵ķ¢Éú¹ý³Ì¡£»ÆÜμ×ÜÕ¿ÉÄÜͨ¹ýÇå³ýÑõ×ÔÓÉ»ù[21-22]£¬¼õÉÙI¦ÊBÁ×Ëữˮ½â£¬ÒÖÖÆºËת¼Òò×Ó¦ÊB·¢ÉúºËÒ×룬´Ó¶ø¼õÉÙϸ°û¼ä𤸽·Ö×Ó1µÄ±í´ï£¬¹ÊÄÚÆ¤Ï¸°ûºËת¼Òò×Ó¦ÊB±í´ï¼õÉÙ£¬ÅàÑøÒºÖÐϸ°û¼ä𤸽·Ö1Ũ¶È½µµÍ£¬ÈËÆê¾²ÂöÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽ÂʽµµÍ¡£

4 ²Î¿¼ÎÄÏ×

1 Chen LX,Zhu HY,Zhu LQ,et al.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2007;11(27):5382-5386
³ÂÁ¢ÐÂ,Ö캣Ñà,ÖìÁêȺ,µÈ.»ÆÜζàÌǶÔÈËÐÄÔà΢Ѫ¹ÜÄÚÆ¤Ï¸°ûÔöÖ³¼°ÔÙ¹à×¢ºóÄÚÆ¤Ï¸°ûÓëÖÐÐÔÁ£Ï¸°û𤸽µÄÓ°Ïì[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´,2007, 11(27):5382-5386
2 Zhu HY,Chen LX,Zhu LQ. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2007,11(41):8255-8258
Ö캣Ñà,³ÂÁ¢ÐÂ,ÖìÁêȺ.ÈËÐÄÔà΢Ѫ¹ÜÄÚÆ¤Ï¸°ûѪ¹Üϸ°û𤸽·Ö×Ó1 ¼°ºËÒò×Ó¦ÊBÔÚȱÑõÔÙ¸´ÑõËðÉ˺óµÄ±í´ïÓë»ÆÜζàÌǵĸÉÔ¤[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´,2007,11(41):8255-8258
3 Meng D,Chen XJ,Yang D,et al.Zhongguo Linchuang Kangfu 2004,8(3):462-463
Ãϵ¤,³ÂÏཡ,ÑîµÑ,µÈ.»ÆÜÎ×ÜÔíß°¶ÔÅàÑø´óÊóÐļ¡Ï¸°û¸Æ³¬ÔصÄÓ°Ïì[J].ÖйúÁÙ´²¿µ¸´,2004,8(3):462-463
4 Gao WZ,Kang Y,Lou JS,et al.Zhongguo Xinxueguan Zazhi 2005,10(3): 166-169
¸ßÎÀÕæ,¿µÒã,¦½¨Ê¯,µÈ.»ÆÜÎÜÕ¢ô¶ÔÐļ¡Ï¸°ûÑõ»¯ËðÉ˵ı£»¤×÷ÓÃ[J].ÖйúÐÄѪ¹ÜÔÓÖ¾,2005,10(3):166-169
5 Sudhiranjan G, David Y, Subha S, et al. Inhibition of NF¦ÊB induces regression of cardiac hypertrophy, independent of blood pressure control in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H20-29
6 Fu XC, Li SP, Wang MW, et al. Protective effects of bamboo leaves extract on ischemia and reperfusion of myocardium. Natural Product Research and Development 2006;18: 214-218
7 Min JK, Kim YM, im SW,et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependen NF-kappa B activation in endothelial cells. J Immunol 2005;175(1):531-540
8 Valen G. Signal transduction through nuclear factor-kappa B activation in ischemia-reperfused and heart failure. Basic Res Cardiol 2004;99(1):1-7
9 Onai Y, Suzuki J, Kakuta T,et al.Inhibition of I¦ÊB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardio res 2004;63:51-59
10 Chamoun F, Bume M, Odonnell M, et al. Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury. Frontiers in bioscience [ectronic resource]: a journal and virtual library 2000;1(5):103-109
11 Kim HJ, Tsoy I, Park JM, et al. Anthocyanins from soybean seed coat inhibit the expression of TNF-alpha-induced genes associated with ischemia/reperfusion in endothelial cell by NF-kappaB-dependent pathway and reduce rat myocardial damages incurred by ischemia and reperfusion in vivo. FEBS Lett 2006;580(5):1391-1397
12 Wang W,Jiang DQ,Qiu XW,et al.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2007£¬11(6):1038-1040
Íõö©,½¯¶«ÇÅ,ÇñЦΥ,µÈ.ȱÑõ/ ¸´ÑõËðÉËÈËÆê¾²ÂöÄÚÆ¤Ï¸°û𤸽·Ö×Ó±í´ïÓëÐÂÐÍÖ²Îï´Æ¼¤ËئÁ£­ÓñÃ׳àù´¼µÄÓ°Ïì[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´,2007,11(6):1038-1040
13 Naito Y, Shimozawa M,anabe H,et al.Azelnidipine: a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol 2006;546(13):11-18
14 Kakkar AK, Lefer DJ. Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004;4(2):154-158
15 Ziegelstein RC, He C, Hu Q.Hypoxia/reoxygenation stimulates Ca2+-dependent ICAM-1 mRNA expression in human aortic endothelial cells. Biochem Biophys Res Commun 2004;322(1):68-73
16 He P, Zhang H, Zhu L, et al. Leukocyte-platelet aggregate adhesion and vascular permeability in intact microvessels: role of activated endothelial cells. Am J Physiol Heart Circ Physiol 2006;291(2):H591-H599
17 Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002£»53(1):31-47
18 Saeed SA, Waqar MA, Zubairi AJ, et al.Myocardial ischaemia and reperfusion Injury: Reactive oxygen species and the role of neutrophil. J Coll Physicians Surg Pak 2005;15(8):507-514
19 Vinten-Johansen J, Jiang R, Reeves JG, et al. Inflammation, proinflammatory mediators and myocardial is chemia-reperfusion injury. Hematol Oncol Clin North Am 2007;21(1):123-145
20 Bhindi R, Khachigian LM, Lowe HC, et al. DNAzymes targeting the transcription factor Egr-1 reduce myocardial infarct size following ischemia-reperfusion in rats. J Thromb Haemost 2006;4(7):1479-1483
21 Zheng PL,Dai JY,Chen H,et al.Zhongguo Yaolixue Tongbao 2005;21(1):1534-1535
Ö£ÅàÀè,´÷½¨ÑÇ,³Âºì,µÈ.»ÆÜμ×ÜÕ¶Ô¼±ÐÔÐÄ˥ȮÐÄÔàÊæËõ¹¦ÄܵÄÓ°Ïì[J].ÖйúÒ©Àíѧͨ±¨,2005,21(1):1534-1535
22 Xu XL,Ji H,Gu SY,et al.Zhongguo Yaoke Daxue Xuebao 2007,38(5): 451-455
ÐíÏþÀÖ,¼¾êÍ,¹ÈÊæâù,µÈ.»ÆÜμ×ÜÕ¶ÔÒì±ûÉöÉÏÏÙËØËùÖÂСÊóÐļ¡·ÊºñµÄ±£»¤×÷ÓÃ[J].ÖйúÒ©¿Æ´óѧѧ±¨,2007,38(5):451-455


¡¶Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´¡·ÔÓÖ¾Éç
µØÖ·£ºÉòÑô1200ÓÊÕþÐÅÏä Óʱࣺ110004 ´«Õ棺+86 24 23394178